BeOne Medicines (BEIGF) Other Working Capital Changes (2017 - 2024)

BeOne Medicines (BEIGF) has reported Other Working Capital Changes for 12 consecutive years, with $8.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Working Capital Changes rose 198.66% year-over-year to $8.2 million in Q2 2026; TTM through Jun 2026 was -$3.7 million, a 117.57% decrease from a year earlier, with the FY2025 full-year figure at -$3.0 million, down 126.45% from the prior year.
• Other Working Capital Changes was $8.2 million for Q2 2026 at BeOne Medicines, up from $6.2 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $282.8 million in Q4 2021 and troughed at -$183.0 million in Q3 2023.
• A 4-year average of $66642.9 and a median of -$23.5 million in 2021 frame the typical range for Other Working Capital Changes.
• Across the five-year window, Other Working Capital Changes soared 677.46% in 2023 and tumbled 3454.67% in 2025, its largest moves.
• Over 5 years, Other Working Capital Changes stood at $1.3 million in 2022, then sank by 1643.04% to -$19.8 million in 2023, then soared by 98.22% to -$353000.0 in 2024, then plunged by 3454.67% to -$12.5 million in 2025, then soared by 165.67% to $8.2 million in 2026.
• The last three Other Working Capital Changes figures came in at $8.2 million (Q2 2026), $6.2 million (Q1 2026), and -$12.5 million (Q4 2025), per Business Quant data.